曲氟尿苷替匹嘧啶片 | China Drugs ListTrifluridine and tipiracil tablets | China Drugs List

本页为公开参考信息,不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。

其他

商品名
Lonsurf
企业
Les Laboratoires Servier (欧盟上市许可持有人)Les Laboratoires Servier (EU authorization holder)
药品类型
化学药Chemical medicine
治疗领域
肿瘤科Oncology
公开来源记录的适应症
欧盟部分适应症:与贝伐珠单抗联合,用于既往接受两种方案的成人转移性结直肠癌,既往方案包括氟嘧啶类、奥沙利铂和伊立替康化疗以及抗VEGF和/或抗EGFR药物。单药用于接受现有治疗后或不适合这些治疗的转移性结直肠癌。也作为单药,用于晚期疾病已接受至少两种全身方案后的转移性胃癌或胃食管结合部癌。本摘要不确立中国批准的适应症范围。Selected EU indications: With bevacizumab, for adults with metastatic colorectal cancer after two previous regimens including fluoropyrimidine, oxaliplatin and irinotecan chemotherapy and anti-VEGF and/or anti-EGFR agents. As monotherapy, for metastatic colorectal cancer after available therapies or when those therapies are unsuitable. Also as monotherapy for metastatic gastric or gastroesophageal junction cancer after at least two systemic regimens for advanced disease. This summary does not establish the approved indications in China.
适应症来源与口径
网页 查阅于 2026-11-02. 部分境外适应症;不确立中国批准范围。Web page accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
说明书信息局限
已链接监管机构产品资料/批准证据;本次核查尚未核实完整的现行处方资料文件。Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
中国可获得性状态
本次英文来源核查未独立核实中国批准、现行中国适应症及持续在售情况。Chinese approval, current Chinese indications and continuous market availability were not independently verified in this English-source review.
海外状态
请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异;尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
医保分类
尚未核实Not yet verified
医保版本
中国国家医保信息待核实Chinese national insurance review pending
医保核查说明
本次新增记录尚未确定报销资格;缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.

来源

证据核查日期:

打开交互详情、公开价格与讨论